The aim of the study. To evaluate the clinical efficacy of combined pharmacotherapy with alendronate sodium and exogenous L-arginine on the background of basic treatment of patients with coronary artery disease (CAD) associated with postmenopausal osteoporosis (PMOP).Material and methods. A double open, prospective, monocentric clinical study in parallel groups involved 58 women in the postmenopausal period with a diagnosis of coronary artery disease: stable angina pectoris II-III FC, who had PMOP (age 71 (65; 77) years). By the method of block randomization, patients were divided into two groups: 1 group – 27 women who received standard basic therapy; 2 group – 31 women who were prescribed a combination of alendronate sodium and L-arginine hydrochloride according to the scheme on the background of basic treatment. The indices of daily ECG monitoring by Holter, structural and functional state of the heart and blood vessels assessment, levels of biomarkers (osteoprotegerin, osteocalcin, homocysteine, VEGF-A) assessment in patients were obtained at study entry and after 3 months of therapy.Results. According to the results of daily ECG monitoring in the dynamics of treatment in patients of both groups there was a significant decrease in the number of episodes of supraventricular arrhythmia per day (by 11.54% and 34.52%, respectively; p<0.05) and the ratio of LF / HF in active and passive period. In patients of group 2 in contrast to group 1, there was also a significant decrease in the number of episodes of tachycardia per day (1.8 times; p<0.05), an increase in RMSSD (by 74.36%; p<0.05), a decrease in LF (by 54.69%; p<0.05) and an increase in HF (by 73.71%; p<0.05) in both active and passive periods. After 3 months of treatment in patients of the 2nd group showed a significant decrease in the IMC thickness of the right CA by 7.95%, the size of the LP by 16.83% compared to baseline (p<0.05), while the 1st group no significant changes in these indicators were observed. Under the influence of treatment in patients of the 2nd group revealed a significant decrease in the level of VEGF-A (by 25.41%; p<0.05), homocysteine (by 10.72%; p<0.05), osteoprotegerin (2 times ; p<0.05), while in patients of the 1st group there was a significant decrease only in the level of VEGF-A (by 20.09%; p<0.05). In patients of group 2 compared with patients of group 1, after 3 months of treatment there were significantly fewer episodes of ventricular and supraventricular arrhythmias, smaller LF meaning, IMC, LA size and greater HF meaning, probably lower levels of osteocalcin, VEGF-A and osteoprotegerin.Conclusions. The use of combined therapy in patients with coronary artery disease, comorbid with PMOP, contributes to positive changes in the autonomic regulation of cardiac activity, structural adjustment of the heart and vascular endothelium, normalization of the balance of biomarkers of osteoreparation and bone resorption.